» Articles » PMID: 17316816

Therapeutic RNA Interference for Neurodegenerative Diseases: From Promise to Progress

Overview
Journal Pharmacol Ther
Specialty Pharmacology
Date 2007 Feb 24
PMID 17316816
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

RNA interference (RNAi) has emerged as a powerful tool to manipulate gene expression in the laboratory. Due to its remarkable discriminating properties, individual genes, or even alleles can be targeted with exquisite specificity in cultured cells or living animals. Among its many potential biomedical applications, silencing of disease-linked genes stands out as a promising therapeutic strategy for many incurable disorders. Neurodegenerative diseases represent one of the more attractive targets for the development of therapeutic RNAi. In this group of diseases, the progressive loss of neurons leads to the gradual appearance of disabling neurological symptoms and premature death. Currently available therapies aim to improve the symptoms but not to halt the process of neurodegeneration. The increasing prevalence and economic burden of some of these diseases, such as Alzheimer's disease (AD) or Parkinson's disease (PD), has boosted the efforts invested in the development of interventions, such as RNAi, aimed at altering their natural course. This review will summarize where we stand in the therapeutic application of RNAi for neurodegenerative diseases. The basic principles of RNAi will be reviewed, focusing on features important for its therapeutic manipulation. Subsequently, a stepwise strategy for the development of therapeutic RNAi will be presented. Finally, the different preclinical trials of therapeutic RNAi completed in disease models will be summarized, stressing the experimental questions that need to be addressed before planning application in human disease.

Citing Articles

DNA methylation patterns in the frontal lobe white matter of multiple system atrophy, Parkinson's disease, and progressive supranuclear palsy: a cross-comparative investigation.

Murthy M, Fodder K, Miki Y, Rambarack N, De Pablo Fernandez E, Pihlstrom L Acta Neuropathol. 2024; 148(1):4.

PMID: 38995454 PMC: 11245434. DOI: 10.1007/s00401-024-02764-4.


The Role of miR-128 in Neurodegenerative Diseases.

Lanza M, Cuzzocrea S, Oddo S, Esposito E, Casili G Int J Mol Sci. 2023; 24(7).

PMID: 37046996 PMC: 10093830. DOI: 10.3390/ijms24076024.


ASPsiRNA: A Resource of ASP-siRNAs Having Therapeutic Potential for Human Genetic Disorders and Algorithm for Prediction of Their Inhibitory Efficacy.

Monga I, Qureshi A, Thakur N, Gupta A, Kumar M G3 (Bethesda). 2017; 7(9):2931-2943.

PMID: 28696921 PMC: 5592921. DOI: 10.1534/g3.117.044024.


Generation of a new transgenic mouse model for assessment of tau gene silencing therapies.

Fromholt S, Reitano C, Brown H, Lewis J, Borchelt D Alzheimers Res Ther. 2016; 8:36.

PMID: 27593210 PMC: 5011353. DOI: 10.1186/s13195-016-0202-1.


CDK5 knockdown prevents hippocampal degeneration and cognitive dysfunction produced by cerebral ischemia.

Gutierrez-Vargas J, Munera A, Cardona-Gomez G J Cereb Blood Flow Metab. 2015; 35(12):1937-49.

PMID: 26104286 PMC: 4671113. DOI: 10.1038/jcbfm.2015.150.